ESMO 2022

Viewing 1-20 of 82 articles

ESMO 2022: Invited Discussant: Results of COSMIC-313

ESMO 2022: Invited Discussant: Results of RADICALS-HD

ESMO 2022: Observations on the Biology of PSMA Implications for Targeting

ESMO 2022: Lu-PSMA for Prostate Cancer Treatment

ESMO 2022: Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers

ESMO 2022: PSMA Targeted T Cell Engagers

ESMO 2022: Multidisciplinary Updates in Biomarkers in Urinary Cancers: The Microbiome

ESMO 2022: Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial

ESMO 2022: Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial

ESMO 2022: PSMA for Diagnosis and Staging

ESMO 2022: Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma of IMDC Intermediate or Poor Risk (COSMIC-313)

ESMO 2022: Duration of Androgen Deprivation Therapy with Post-Operative Radiotherapy for Prostate Cancer First Results of the RADICALS-HD Trial ISRCTN40814031

ESMO 2022: Invited Discussant: BIONIKK trial, Changes in Gut Microbiota, & LITESPARK-004 trial

ESMO 2022: Invited Discussant: Results of the Phase 2 LITESPARK-003 Trial

ESMO 2022: Longitudinal Analysis Reveals Gut Microbiota Shift During Standard Therapies in Metastatic Renal Cell Carcinoma (mRCC)

ESMO 2022: Invited Discussant: The Results of the PIVOT-09 Trial & the Role of Enfortumab Vedotin

ESMO 2022: Phase 2 Study of Belzutifan plus Cabozantinib as First-Line Treatment of Advanced Renal Cell Carcinoma Cohort 1 of LITESPARK-003

ESMO 2022: Bempegaldesleukin plus Nivolumab Compared to the Investigator’s Choice of Sunitinib or Cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma Results from a Phase 3 Randomized Study

ESMO 2022: Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin Monotherapy or in Combination with Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

ESMO 2022: Tumor and Immune Features Associated with Disease-Free Survival with Adjuvant Nivolumab in the Phase 3 CheckMate 274 Trial

1
2
3
4
5